Table 2.
Baseline characteristics.
| Nr | First Author |
Demography |
MS data |
Disease Modifying Treatments |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample | Females/Males | Age, yrs (range) | Progressive/RR | Last EDSS | MS duration, yrs(range) | DMT unknown | Untreated | Cladribine | Alemtuzumab | Azathioprine | Glatiramer Acetate | Dimethyl fumarate | Fingolimod | Interferon beta | Methotrexate | Mitoxantrone | Natalizumab | Ocrelizumab | Rituximab | Teriflunomide | Ozanimod | Other | ||
| 01 | Louapre C. | 347 | 249/98 | 31.8-57.4 | 65/282 | 2.0 | 3.5-23.5 | 63 | 3 | 1 | 0 | 33 | 35 | 42 | 20 | 1 | 0 | 57 | 38 | 17 | 33 | 0 | 4 | |
| 02 | Oreja-Guevara C. | 14 | 9/5 | 28.1-52.1 | 1/13 | 1.0 | 0.8-18.6 | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 03 | Hervás-García J. V. | 19 | 12/7 | 41-67 | 1/18 | 2.0 | 3-24 | 0 | 0 | 1 | 1 | 0 | 0 | 5 | 2 | 3 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 0 |
| 04 | Salter A. | 1626 | 1202/421 | 34.5-60.9 | 280/1275 | 3.2-23 | 237 | 14 | 9 | 84 | 208 | 106 | 53 | 2 | 0 | 170 | 484 | 77 | 82 | 1 | 41 | |||
| 05 | Czarnowska A. | 396 | 282/114 | 18-68 | 24/372 | 2.0 | 0-33 | 0 | 5 | 1 | 0 | 42 | 164 | 16 | 82 | 0 | 3 | 35 | 20 | 0 | 25 | 3 | 0 | |
| 06 | Sormani M. P. | 844 | 593/251 | 18-82 | 135/676 | 2.0 | 4.7-17.1 | 151 | 11 | 14 | 10 | 70 | 174 | 94 | 73 | 1 | 1 | 85 | 89 | 5 | 64 | 0 | 2 | |
| 07 | Arrambide G. | 326 | 221/105 | 33.3-56.3 | 63/263 | 2.0 | 3-19 | 59 | 6 | 18 | 0 | 13 | 41 | 27 | 36 | 0 | 0 | 26 | 23 | 33 | 37 | 7 | ||
| 08 | Spelman T. | 476 | 340/136 | 19–78 | 67/407 | 2.0 | 0.0–40.7 | 18 | 8 | 5 | 9 | 48 | 20 | 18 | 57 | 7 | 262 | 11 | 13 | |||||
| 09 | Drulovic J. | 18 | 13/5 | 33-51.1 | 0/18 | 3.0 | 6.6-22.2 | 0 | 11(+7)* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 10 | Fragoso Y. D. | 73 | 50/23 | 17-72 | 4/69 | 2.0 | 0-26 | 0 | 3 | 1 | 1 | 0 | 10 | 15 | 14 | 10 | 0 | 0 | 6 | 5 | 3 | 5 | 0 | 0 |
| 11 | Bsteh G. | 126 | 90/36 | 21-79 | 28/98 | 2.0 | 8 | 37 | 2 | 2 | 1 | 11 | 19 | 16 | 6 | 0 | 0 | 10 | 12 | 2 | 0 | 0 | ||
| 12 | Perez A. C. | 843 | 616/227 | 39.8-70.6 | 511 | 51 | 1 | 1 | 55 | 45 | 14 | 26 | 18 | 72 | 17 | 24 | 1 | 7 | ||||||
| 13 | Yavorskaya V. | 30 | 25/5 | 19-55 | 0 | 0 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
⁎
Out of 18 patients in treatment with Cladribine, 11 developed COVID-19 infection. In some manuscripts DMTs and/or MS type are not available for all individuals